• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Introduction to 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine (CAS No. 1190319-51-7)

6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine (CAS No. 1190319-51-7) is a versatile compound with significant potential in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrrolopyridines, which are known for their diverse biological activities and structural flexibility. The presence of a bromine atom and a methyl group in its structure makes it an attractive scaffold for the development of novel therapeutic agents.

The chemical structure of 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine is characterized by a fused pyrrole and pyridine ring system, with a bromine substituent at the 6-position and a methyl group at the 2-position. This unique arrangement of functional groups imparts specific chemical and biological properties that have been the focus of numerous studies in recent years.

In the context of medicinal chemistry, 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine has been explored as a lead compound for the development of drugs targeting various diseases. One notable area of research is its potential as an inhibitor of kinases, which are enzymes involved in cell signaling pathways and are often dysregulated in cancer and other diseases. Studies have shown that derivatives of this compound can selectively inhibit specific kinases, making them promising candidates for cancer therapy.

Recent advancements in the field have also highlighted the role of 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine in modulating other biological targets. For instance, research has demonstrated its ability to interact with G protein-coupled receptors (GPCRs), which are key players in many physiological processes and therapeutic targets for a wide range of conditions, including cardiovascular diseases, neurological disorders, and metabolic syndromes.

The synthetic accessibility of 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine has further contributed to its popularity in drug discovery programs. Various synthetic routes have been developed to efficiently produce this compound and its derivatives, allowing researchers to explore a wide range of structural modifications to optimize biological activity and pharmacokinetic properties. One such method involves the use of palladium-catalyzed cross-coupling reactions, which have proven to be highly effective in constructing complex pyrrolopyridine frameworks.

In addition to its potential as a therapeutic agent, 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine has also been studied for its utility as a probe molecule in chemical biology. Its ability to selectively bind to specific protein targets makes it valuable for understanding protein function and identifying new drug targets. For example, it has been used in high-throughput screening assays to identify small molecules that modulate protein-protein interactions or enzyme activities.

The safety profile of 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine is another important consideration in its development as a pharmaceutical agent. Preclinical studies have generally shown favorable safety margins, with no significant toxicity observed at therapeutic concentrations. However, ongoing research is necessary to fully evaluate its long-term safety and efficacy in human subjects.

In conclusion, 6-Bromo-2-methyl-1H-pyrrolo[3,2-b]pyridine (CAS No. 1190319-51-7) represents a promising scaffold for the development of novel drugs with diverse therapeutic applications. Its unique chemical structure, combined with its synthetic accessibility and favorable biological properties, positions it as an important compound in the ongoing efforts to advance medicinal chemistry and pharmaceutical research.

• 1257294-45-3(4-bromo-5-methyl-1H-Pyrrolo[2,3-c]pyridine)
• 869012-93-1(3-bromo-2-methyl-1H-Pyrrolo[2,3-c]pyridine)
• 1082042-20-3(7-Bromo-4-methyl-1H-pyrrolo[3,2-c]pyridine)
• 1190316-53-0(3-Bromo-7-methyl-1H-pyrrolo[2,3-c]pyridine)
• 1679330-47-2(3-Bromo-5-methyl-1H-pyrrolo[2,3-c]pyridine)
• 1000342-72-2(3-Bromo-4-methyl-5-azaindole)
• 1000343-73-6(3-Bromo-5-methyl-4-azaindole)
• 1049030-25-2(5-Bromo-6-methyl-1,7-naphthyridine)
• 1190313-09-7(3-Bromo-6-methyl-5-azaindole)
• 1257294-43-1(4-bromo-7-methyl-1H-Pyrrolo[2,3-c]pyridine)